0.6387
Ocugen Inc stock is traded at $0.6387, with a volume of 3.74M.
It is down -7.30% in the last 24 hours and up +5.55% over the past month.
See More
Previous Close:
$0.689
Open:
$0.6562
24h Volume:
3.74M
Relative Volume:
0.93
Market Cap:
$186.51M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.3656
EPS:
-0.27
Net Cash Flow:
$-72.53M
1W Performance:
-11.77%
1M Performance:
+5.55%
6M Performance:
-32.59%
1Y Performance:
-57.56%
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
OCGN
Ocugen Inc
|
0.6387 | 186.51M | 0 | -63.08M | -72.53M | -0.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-15-24 | Initiated | Maxim Group | Buy |
Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Aug-23-22 | Initiated | Mizuho | Buy |
Jun-15-22 | Resumed | ROTH Capital | Buy |
Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results - MSN
Stock Quote & Chart - Ocugen
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 - Yahoo
Ocugen’s OCU200 advances to next trial phase with safety approval By Investing.com - Investing.com Australia
ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN - Business Wire
OCGN stock touches 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa
OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com India
Ocugen Advances OCU200 Trial After Safety Board Review -March 18, 2025 at 08:31 am EDT - Marketscreener.com
Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial - TipRanks
Ocugen’s OCU200 advances to next trial phase with safety approval - Investing.com India
Ocugen Announces Approval to Continue Dosing in Phase 1 Trial of OCU200 Following Favorable Safety Review - Nasdaq
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - Ocugen
Data and Safety Monitoring Board Reviews Cohort 1 Safety - GlobeNewswire
Ocugen seeks its One Shining Moment - The Healthcare Technology Report.
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial - MSN
Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN
SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World
Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World
FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World
Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs - MSN
Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating -March 06, 2025 at 08:15 am EST - Marketscreener.com
Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocugen’s Strategic BLA Submissions and Financial Position Support Buy Rating - TipRanks
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock - Benzinga
Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen: Q4 Earnings Snapshot - Midland Daily News
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ocugen Inc Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks
Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025 - CGTLive™
Ocugen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ocugen (OCGN) Q4 2024 Earnings Call Transcript - Yahoo
Ocugen’s Geographic Atrophy and Stargardt Gene Therapies Garner Positive ATMP Opinions from EMA - CGTLive™
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast By Investing.com - Investing.com UK
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MSN
Ocugen, Inc. SEC 10-K Report - TradingView
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):